Video: Sitting Down With… John Tomtishen

• October 7, 2026

FDA grants Temab-A dual Breakthrough status

The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.

• by Mouj Hijazi

• October 7, 2026

• 3 min

Which States Will Be Affected by Key Medicaid Provisions in the 2025 Reconciliation Law?

• by Alice Burns, Jennifer Tolbert, Robin Rudowitz, Anthony Montano

• October 7, 2026

Associations between CT characteristics of lung cancer lesions and histologic subtypes in lung cancer screening

• by Erick Suazo-Zepeda, Geertruida H. de Bock, Noa Antonissen, Colin Jacobs, Firdaus A. A. Mohamed Hoesein, Hester A. Gietema, Grigory Sidorenkov, Rozemarijn Vliegenthart, Marjolein A. Heuvelmans

• October 7, 2026